We are re-imagining this essential forum from a live in-person event to an interactive virtual format, designed to bring clarity to some of the greatest challenges facing manufacturers, patients, and payers alike in this radically altered healthcare climate.

WHAT TO EXPECT AT OUR NEW VIRTUAL CONFERENCE
Icon

Enjoy an Easy to Use, Dynamic Online Platform

Icon

Immerse Yourself in Live Presentations and Panel Discussions

Icon

Engage with Attendees and Speakers in an Interactive Format

Icon

Meet 1-on-1 with Your Fellow Attendees

Sweeping changes are coming to how drugs are priced, procured and reimbursed in Canada but many of the details have yet to be solidified. While the industry grapples with these ongoing changes, a global pandemic has created a new focal point: identifying viable COVID-19 treatments and supporting scientific advancements towards vaccine.

It’s a critical time for stakeholders to come together and learn about how regulatory bodies could potentially work together under a National Drug Agency and the implications of new pricing ceilings.

At this juncture, collaboration and transparency are paramount to patient access and improved health outcomes. Join us this February and to build your pricing and access strategy for 2020 and beyond through conversations and in-depth analysis about:

  • OPTIMIZING pCPA negotiations with advice on current and impending policy positions
  • UNDERSTANDING how PMPRB reform and National Pharmacare models could impact the Canadian market
  • ASSESSING the emergence of new HTA frameworks
  • IDENTIFY OPPORTUNITIES to create partnerships and advance your market access strategy
Meet the Co-Chairs
Speaker Name

Alexis Sciuk

Director of Access & Government Relations
Pfizer

Speaker Name

Rosemarie Childerhose

Director, Market Access & Government Affairs
Bausch Health

FEATURED SESSIONS

Forecasting Future Pathways for Access in the Canadian Market

Preparing for PMPRB Final Guidelines: A Practical Examination of the Impact on Drug Pricing in Canada

Private Payers Panel: Approaches to Reimbursement for Advanced Therapeutics

TIMELY INSIGHTS FROM
  • PMPRB
  • Pfizer
  • Canada Life
  • Crohn’s & Colitis Canada
  • CADTH
  • Health Canada
  • Sun Life
Top Reasons to Attend
  • Get direction on the latest changes to drug reviews and pricing ceilings to better inform market access and pricing strategies
  • Gain insights on reimbursement regimes though Q & A with public and private payers
  • Walk away with an understanding of how to bring innovative solutions to market
  • Hear how other jurisdictions are approaching HTA and pricing negotiations
  • Learn about developments in precision medicine that could increase the safety and efficacy of treatments while reducing healthcare spending

Register now to attend this forward-looking forum, designed to bring clarity to some of the greatest challenges facing manufacturers, patients and payers alike.

REGISTER NOW
Past Attending Organizations Include
  • Sidley & Austin LLP
  • Paladin Labs Inc
  • Boehringer Ingelheim Canada Ltd
  • Clinical Trials Ontario
  • Sun Life Financial
  • Green Shield Canada
  • PIVINA Consulting Inc
  • LifeLabs
  • Amgen Canada Inc
  • Pan-Canadian Pharmaceutical Alliance
  • Canopy Growth Corporation
  • Otsuka Canada Pharmaceutical Inc
  • Norton Rose Fulbright Canada LLP
  • GSK
  • PMPRB
  • Cancer Care Ontario
  • Bristol Myers Squibb
  • Cornerstone Research Group
  • CADTH
  • Novartis Canada
  • Sandoz Canada Inc
  • Innovative Medicines Canada
  • Ipsen Biopharmaceuticals Canada
  • Equitable Life of Canada
  • SteriMax
  • Brougham Consulting Inc
  • Osler Hoskin & Harcourt LLP
  • Canadian Organization for Rare Disorders
  • Leslie Dan Faculty of Pharmacy
  • GlaxoSmithKline Plc
  • RWW Consultants
  • PENDOPHARM
  • AstraZeneca Canada Inc
  • Innomar Strategies Inc
  • AbbVie Corporation
  • INESSS
  • Great West Life
  • Jamp Pharma Corporation